This led to additional pilot funding from the Irving Institute and the Basser Center to expand work on use of the decision aid among Orthodox Jewish women eligible for BRCA1/2 testing and evaluate mental illness as a barrier to genetic testing [18–20]. The gene discussed is BRCA1; the disease is psychiatric disorder.